TWI563004B - Anti-hxcr1 antibody - Google Patents

Anti-hxcr1 antibody

Info

Publication number
TWI563004B
TWI563004B TW101131633A TW101131633A TWI563004B TW I563004 B TWI563004 B TW I563004B TW 101131633 A TW101131633 A TW 101131633A TW 101131633 A TW101131633 A TW 101131633A TW I563004 B TWI563004 B TW I563004B
Authority
TW
Taiwan
Prior art keywords
hxcr1
antibody
hxcr1 antibody
Prior art date
Application number
TW101131633A
Other languages
English (en)
Chinese (zh)
Other versions
TW201311725A (zh
Inventor
Yoshimasa Sakamoto
Miyuki Nishimura
Tetsu Kawano
Yukihisa Sawa
Toshio Imai
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of TW201311725A publication Critical patent/TW201311725A/zh
Application granted granted Critical
Publication of TWI563004B publication Critical patent/TWI563004B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW101131633A 2011-09-01 2012-08-30 Anti-hxcr1 antibody TWI563004B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161530194P 2011-09-01 2011-09-01
US201261659637P 2012-06-14 2012-06-14

Publications (2)

Publication Number Publication Date
TW201311725A TW201311725A (zh) 2013-03-16
TWI563004B true TWI563004B (en) 2016-12-21

Family

ID=46881120

Family Applications (1)

Application Number Title Priority Date Filing Date
TW101131633A TWI563004B (en) 2011-09-01 2012-08-30 Anti-hxcr1 antibody

Country Status (19)

Country Link
US (1) US9371389B2 (enExample)
EP (1) EP2751140B1 (enExample)
JP (1) JP5989096B2 (enExample)
KR (1) KR101767717B1 (enExample)
CN (1) CN103764680B (enExample)
AR (1) AR087749A1 (enExample)
AU (1) AU2012302596B2 (enExample)
BR (1) BR112014004352A2 (enExample)
CA (1) CA2846370C (enExample)
ES (1) ES2684173T3 (enExample)
HK (1) HK1199038A1 (enExample)
IL (1) IL231075A (enExample)
IN (1) IN2014CN01466A (enExample)
MX (1) MX346560B (enExample)
MY (1) MY166152A (enExample)
PH (1) PH12014500384A1 (enExample)
RU (1) RU2619180C2 (enExample)
TW (1) TWI563004B (enExample)
WO (1) WO2013032032A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014208987A1 (ko) 2013-06-24 2014-12-31 한화케미칼 주식회사 안정성이 개선된 항체-약물 결합체 및 이의 용도
CA2994629A1 (en) * 2015-08-05 2017-02-09 Acticor Biotech Novel anti-human gpvi antibodies and uses thereof
IL268299B2 (en) 2017-02-03 2024-10-01 Acticor Biotech Inhibition of platelet aggregation using anti-human gpvi antibodies
CA3050601A1 (en) 2017-02-07 2018-08-16 Vib Vzm Immune-cell targeted bispecific chimeric proteins and uses thereof
CN107312092B (zh) * 2017-05-04 2020-12-11 华南农业大学 一种斜带石斑鱼ccr12的多克隆抗体制备方法及其应用
WO2019068099A1 (en) * 2017-09-29 2019-04-04 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR MODULATION OF LYMPHOCYTE ACTIVITY SUPPRESSION
EP3743448A4 (en) * 2018-01-26 2021-11-03 Orionis Biosciences, Inc. XCR1 BINDING AGENTS AND USES THEREOF
CA3118892A1 (en) 2018-11-08 2020-05-14 Orionis Biosciences, Inc. Modulation of dendritic cell lineages
WO2020136060A1 (en) 2018-12-28 2020-07-02 F. Hoffmann-La Roche Ag A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009065561A2 (en) * 2007-11-20 2009-05-28 Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch-Institut System for delivery into a xcr1 positive cell and uses thereof
EP2149582A1 (en) * 2007-04-24 2010-02-03 Shanghai National Engineering Research Center of Antibody Medicine Co., Ltd. Osteopontin functional epitopes, monoclonal antibodies against the epitopes and uses thereof
US20100303808A1 (en) * 2009-02-16 2010-12-02 Williams David G Humanized anti-cd20 antibodies and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5786210A (en) 1994-02-08 1998-07-28 Schering Corporation Mammalian thymokine genes
AU2001250412A1 (en) * 2000-03-31 2001-10-08 Ipf Pharmaceuticals Gmbh Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using specific chemokine receptor analysis and the chemokine receptor-ligand interaction
WO2002059608A2 (en) * 2000-11-29 2002-08-01 Lifespan Biosciences, Inc. Compositions and methods related to chemokine (c motif) xc receptor 1 (ccxcr1)
US20050136033A9 (en) 2002-08-13 2005-06-23 Matthias Mack Method of treating allergen induced airway disease
WO2004072646A1 (en) * 2003-02-13 2004-08-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 5 (gpr5)
EP1698902A1 (en) * 2005-03-01 2006-09-06 DKFZ Deutsches Krebsforschungszentrum Use of XCR1 for diagnosing or monitoring of immune tolerance

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2149582A1 (en) * 2007-04-24 2010-02-03 Shanghai National Engineering Research Center of Antibody Medicine Co., Ltd. Osteopontin functional epitopes, monoclonal antibodies against the epitopes and uses thereof
WO2009065561A2 (en) * 2007-11-20 2009-05-28 Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch-Institut System for delivery into a xcr1 positive cell and uses thereof
US20100303808A1 (en) * 2009-02-16 2010-12-02 Williams David G Humanized anti-cd20 antibodies and methods of use

Also Published As

Publication number Publication date
PH12014500384A1 (en) 2014-04-14
JP2014527396A (ja) 2014-10-16
JP5989096B2 (ja) 2016-09-07
HK1199038A1 (en) 2015-06-19
WO2013032032A1 (en) 2013-03-07
CA2846370A1 (en) 2013-03-07
EP2751140B1 (en) 2018-05-30
KR20140054108A (ko) 2014-05-08
CA2846370C (en) 2019-04-23
AU2012302596A1 (en) 2014-03-06
CN103764680A (zh) 2014-04-30
RU2619180C2 (ru) 2017-05-12
US9371389B2 (en) 2016-06-21
IL231075A (en) 2017-08-31
TW201311725A (zh) 2013-03-16
IL231075A0 (en) 2014-03-31
IN2014CN01466A (enExample) 2015-05-08
AR087749A1 (es) 2014-04-16
ES2684173T3 (es) 2018-10-01
BR112014004352A2 (pt) 2017-03-21
KR101767717B1 (ko) 2017-08-11
MY166152A (en) 2018-06-06
RU2014106832A (ru) 2015-08-27
NZ621320A (en) 2015-11-27
MX2014002078A (es) 2014-05-30
EP2751140A1 (en) 2014-07-09
CN103764680B (zh) 2016-11-23
AU2012302596B2 (en) 2016-12-01
US20140193421A1 (en) 2014-07-10
MX346560B (es) 2017-03-24

Similar Documents

Publication Publication Date Title
IL272035A (en) Anti IL–36R antibodies
IL259826A (en) Anti-alphabetatisiar antibody
ZA201307983B (en) Anti-b7-h3 antibody
GB201103955D0 (en) Antibodies
GB201112056D0 (en) Antibodies
ZA201307642B (en) Immunoassay
PT2581113T (pt) Anticorpo anti-tim-3
LT3342786T (lt) Anti-dll3 antikūnai
EP2722343A4 (en) ANTI-ERBB3 ANTIBODIES
PL2616489T3 (pl) Przeciwciało anty-huTNFR1
ZA201407316B (en) Anti-fgfr2 antibody
ZA201407079B (en) Cdr-modified anti-siglec-15 antibody
TWI563004B (en) Anti-hxcr1 antibody
GB201220242D0 (en) Antibody
GB201112395D0 (en) Immunoassay
EP2714074A4 (en) ANTIBODIES AGAINST EMR1
EP2811018A4 (en) ANTI-BODY ANTI-sAPPß
GB201007957D0 (en) Antibody
GB201116342D0 (en) Antigen combinations
GB201017780D0 (en) Antibody

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees